Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection

NCT02038881 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
87
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Bavarian Nordic